In a recent report, the President’s Council of Advisors on Science and Technology advocate using biomarkers to streamline clinical trials and reduce the cost of drug development by helping improve information related to drug safety and effectiveness. They recommend using validated biomarkers in the following applications to propel scientific innovation and drug discovery development and evaluation: predict efficacy and toxicity, stratify patients, monitor disease progression and diagnose patients.
